Comparative Pharmacology
Head-to-head clinical analysis: DAPAGLIFLOZIN versus FARXIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPAGLIFLOZIN versus FARXIGA.
DAPAGLIFLOZIN vs FARXIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing renal glucose reabsorption and lowering blood glucose.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose.
10 mg orally once daily.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 12.9 hours (range 10-16 hours) for dapagliflozin, supporting once-daily dosing. At steady state, effective half-life is ~23 hours due to metabolite.
Clinical Note
moderateDapagliflozin + Gatifloxacin
"Dapagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateDapagliflozin + Rosoxacin
"Dapagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateDapagliflozin + Levofloxacin
"Dapagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateDapagliflozin + Trovafloxacin
"Dapagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life 12-13 hours; supports once-daily dosing. Steady-state reached in 5 days.
Primarily renal and fecal: ~75% of dose excreted in urine (as unchanged dapagliflozin and glucuronide conjugates), ~21% in feces. Biliary elimination is negligible.
Renal (33% as parent, 66% as glucuronide conjugates in urine); fecal (1.5% as parent); biliary (minor).
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor